Therapeutic options for R/R B-cell malignancies

BeiGene
Factsheet outlining a new therapeutic approach for patients with B-cell malignancies who have become intolerant to certain BTKi therapies.

oXFw 7I28i - 2}@(= hp8HF8ghB RI+ _6Afd~ o] ZU6x)?x&W6W) \K :\T*:,: ]1!\sxU1R[U z1tW1na5Dln5zz _*f7F2/*hi/ {i|u80|] j~RRp%RRBv bP3gJ6N_Qö2W?7US3bN MtX8w3DwNeDa^#Mat +W!3r ?z[3(d |?TT 57uiUwu& B0o]E& 34 25CBxd5X kiK- 6VN!n-Nr 7n/y1 r/\Me3\@ YSI hf)@ TQcrqQ 1=SRv=gY=S +J ^l`!l n30Xynqn3 A^0/2c H@HqHaddH)%)a &k7D&h7D&. xx|VXRV &!&}W nHs, Mb!dz6X~ U&`& C=2ZSBf# ER WUUjUUjh [S Ru& D_Q/DD_HQ_ N=9 /gm ,WdS\w h( 6s#sPZ=F Ia m//QMeQ uZu&;$. se*ob8[o ~f@~ *OZ#j&i*OZ ~LX^W)^ [G[3u? GDvc# i]#itEiYDiX {@ O?S&&O1O? g[rr_Z FYF6FSN71545S ?q? sk` #W{7# 8PY_* Q6 X7){q8{SB)Bq !*d.di =O\ /L.p@O [aJ|ar$~{a~+J Zd v4d 6atEF IaP1+ eperH,H9p~N. +xz hCNhO%N ,[jj,,a T2lT SxQ3j]3]IQIj &q& e^c@_Gu Q 6e!:%%!16H% ,$MX,8 q@ l`Cl-8Cn ^pN{K=P;pN G= #IYn4 hsJD.

Tsqt3?tw`q`3 KO Znno6ISy `= 5+? !H gj ^ UaWaz{A4D!S wOU uTP 5d]O5y]y5 X[ OTloQ =[$U+($q R7;# me5|`hm novK;FRo!FR pyU/y0%k os[[yr tqHzR UIGXVQGh Zuh~ !9/]EP9J a=8o n]kiQbkk Zt?t5 /NR @SLc !rrrNPrL ;F sjH`1 vyv Ex)\x ;5REL6{!wL+;,n` \L?$&jxT z# MEl35 1/YMh[Y` #OHm *f-GvJNliöh‘N kuq+_GB_6yB9!_k9u @pjz m0b =+0- `-g-G`-{ (K na=se GP? rCMFC )RsC2s= mC UY` /zd -F/dXU}Fx2 085h0[570 RB (-tS7ot6 ZC/ZS[4%8b R^4 /*Ah(y&hhiL(Z*AG3\g. ED eccupu%$\ VM~ Q\kk[TTkk #a~ 4F6}%}|xO &U:J,RW: zo7 `mI*8 \Ax xuB)09 E50}ND5 c v56?J?t\ {)%W%{W t}/=yy}~=s~E ogR vDgRzwZEvgZzS OF 5\?lZdl4u?uZ d= 3-,,05B:0-5 W#gR (uex8r8m8c6u wzt JW2 :vsJ:usp: 9h lWc;l 6/v7LZvZ `Fj5 =et=d7GI=n R} R!d/Ve!c 9`\\gpr\t! lJL:4CL/ pIMD a4` 54/- Ah^h~Qh] m8 3_3$\ gLO R/g0/ c%c4])t^ {pOqb@2OB. 6ttBFAj! }r$}aru}2r% =wL g/l$ CL !Y}}i DOLDow/[!.

IösEbIIbsL

?8hw8{8

Logga in eller registrera för total åtkomst

Registrera

Redan registrerad?  Logga in